VERAXA's Novel BiTAC Platform has the Potential to Deliver Multiple Next-Generation Solid Tumor Cancer Therapies, Including Novel Antibody-Drug Conjugate ("ADC") and Bispecific T-cell Engager ("TCE") Candidates, with Strong and Differentiated Clinical ProfilesCompany Pursuing Multiple Strategic Partnerships and Licensing Opportunities in 2025 and 2026Transaction Values VERAXA at a Pre-money Equity Value of $1.3 BillionActively Working with Existing and New VERAXA Investors to Raise a Crossover Financing Round, which is Expected to Close Ahead of the Business Combination, Alongside up to $253 Million in Cash Held in TrustBusiness Combination is Expected to be Completed in the Fourth Quarter o
425 - Voyager Acquisition Corp./Cayman Islands (0002006815) (Subject)
8-K - Voyager Acquisition Corp./Cayman Islands (0002006815) (Filer)
10-K - Voyager Acquisition Corp./Cayman Islands (0002006815) (Filer)
SCHEDULE 13G/A - Voyager Acquisition Corp./Cayman Islands (0002006815) (Subject)
SCHEDULE 13G - Voyager Acquisition Corp./Cayman Islands (0002006815) (Subject)
SCHEDULE 13G - Voyager Acquisition Corp./Cayman Islands (0002006815) (Subject)
SCHEDULE 13G - Voyager Acquisition Corp./Cayman Islands (0002006815) (Subject)
SCHEDULE 13G/A - Voyager Acquisition Corp./Cayman Islands (0002006815) (Subject)
SCHEDULE 13G/A - Voyager Acquisition Corp./Cayman Islands (0002006815) (Subject)
10-Q - Voyager Acquisition Corp./Cayman Islands (0002006815) (Filer)
SC 13G - Voyager Acquisition Corp./Cayman Islands (0002006815) (Subject)
SC 13G - Voyager Acquisition Corp./Cayman Islands (0002006815) (Subject)
SC 13G/A - Voyager Acquisition Corp./Cayman Islands (0002006815) (Subject)
SC 13G - Voyager Acquisition Corp./Cayman Islands (0002006815) (Subject)
SC 13G/A - Voyager Acquisition Corp./Cayman Islands (0002006815) (Subject)